Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Enzolytics Inc
(OP:
ENZC
)
0.0004
UNCHANGED
Streaming Delayed Price
Updated: 3:40 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enzolytics Inc
< Previous
1
2
3
Next >
Enzolytics, Inc. Reports Progress and Future Plans
April 25, 2022
COLLEGE STATION, TX / ACCESSWIRE / April 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics continues to make significant progress in its multiple therapeutic platforms...
From
Enzolytics, Inc.
Via
AccessWire
Enzolytics IPF Immune(TM) Introduced to Large and Small Retail Buyers at Recent ECRM "Weight Management, Nutrition, and Vitamin Program"
April 11, 2022
COLLEGE STATION, TX / ACCESSWIRE / April 11, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Large and small retail buyers were introduced to Enzolytics IPF Immune™, an immune...
From
Enzolytics, Inc.
Via
AccessWire
Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS-CoV-2 and HIV Viruses
March 25, 2022
COLLEGE STATION, TX / ACCESSWIRE / March 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/.) In submissions under the Patent Cooperation Treaty (PCT), Enzolytics, Inc. has pending...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Intellectual Property
Enzolytics, Inc. Highlights the Introduction of IPF Immune(TM) as CRN Data Shows Record-Breaking Number of Americans Use Dietary Supplements
March 23, 2022
COLLEGE STATION, TX / ACCESSWIRE / March 23, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). 80 Percent of Americans Now Use Nutritional Supplements; Interest in Immunity Protection...
From
Enzolytics, Inc.
Via
AccessWire
Enzolytics, Inc.'s Wholly Owned Subsidiary Virogentics, Inc. Reports Progress on the Delivery of its ITV-1 Anti-HIV Therapeutic for Use by Patients in African Regions
March 14, 2022
COLLEGE STATION, TX / ACCESSWIRE / March 14, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) Enzolytics' ("ENZC") wholly-owned subsidiary Virogentics, Inc. (the "Subsidiary") today...
From
Enzolytics, Inc.
Via
AccessWire
Enzolytics IPF Immune(TM), an Immune Modulator, Is Introduced into the U.S. Market This Month
March 10, 2022
COLLEGE STATION, TX / ACCESSWIRE / March 10, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) announces that Enzolytics IPF Immune™, its immune modulator, will be introduced into the...
From
Enzolytics, Inc.
Via
AccessWire
Enzolytics, Inc. Announces New Advisory Board Member
February 28, 2022
COLLEGE STATION, TX / ACCESSWIRE / February 28, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) announces the addition of Dr. Suraj Kumar Saggar to its Advisory Board. Dr. Saggar...
From
Enzolytics, Inc.
Via
AccessWire
Enzolytics Announces Its New Technology For Entry Into The In-Vitro Diagnostics Market
February 21, 2022
COLLEGE STATION, TX / ACCESSWIRE / February 21, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) announces its plans for entry into the diagnostics market. Enzolytics has filed a...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Enzolytics, Inc. Announces Production and Sale in North America of “Enzolytics IPF Immune(TM)”, A New Dietary Supplement That Enhances the Immune System
January 04, 2022
COLLEGE STATION, TX / ACCESSWIRE / January 4, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) announces production and sale in the U.S. and North America of "Enzolytics IPF Immune™,"...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Intellectual Property
Enzolytics Reports Its Engagement of Scendea USA, Inc., a Leading International Product Development and Regulatory Consulting Group, To Guide the Progress Toward Clinical Trials and Market Approval for Its Itv-1 Anti-HIV Therapeutic
December 29, 2021
COLLEGE STATION, TX / ACCESSWIRE / December 29, 2021 / Enzolytics, Inc. has engaged Scendea USA, Inc. (www.scendea.com), a leading international product development and regulatory consulting group, to...
From
Enzolytics, Inc.
Via
AccessWire
Enzolytics Announces Progress As It Recognizes World AIDS Day
December 02, 2021
COLLEGE STATION, TX / ACCESSWIRE / December 2, 2021 / Enzolytics wishes to recognize and acknowledge World AIDS Day - a day to call attention to the continued need for a more effective treatment for...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Regulatory Compliance
Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a Tested Immune Modulator based on U.S. Patent No. 8,309,072
November 17, 2021
COLLEGE STATION, TX / ACCESSWIRE / November 17, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced planned production and sale in the U.S. and North America of "Enzolytics...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Enzolytics, Inc. Announces Program for Creation of Multiple Monoclonal Antibodies for Veterinary Application Utilizing Hybridoma and Phage Display Technology
November 08, 2021
COLLEGE STATION, TX / ACCESSWIRE / November 8, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced a coherent protocol that it is executing to meet the Company's objective...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Enzolytics Reports Its Progress Toward Completion Of Clinical Trials for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency
July 29, 2021
COLLEGE STATION, TX / ACCESSWIRE / July 29, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has completed arrangements and agreements with Danhson (https://danhson.bg/en/) and Clinic...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Enzolytics Announces the Appointment of Steve Sharabura as President of its Wholly Owned Subsidiary RobustoMed, Inc (A/K/A ENZO SUB)
July 26, 2021
COLLEGE STATION, TX / ACCESSWIRE / July 26, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) ("Enzolytics" and the "Company") announced today the appointment of Steve Sharabura as President of the Company's...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
July 21, 2021
COLLEGE STATION, TX / ACCESSWIRE / July 21, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) Enzolytics and Lonza Bioscience are combining their respective technologies to fast-track development and production...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc. for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
July 20, 2021
COLLEGE STATION, TX / ACCESSWIRE / July 20, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) ("Enzolytics" and the 'Company') announces the signing of a Letter of Intent (LOI) with Creative Biolabs ("Creative")...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Enzolytics Announces Its Progress Toward Completion of Clinical Trials for Its Anti-HIV ITV-1 Therapeutic and Plans for Its Distribution Throughout Europe
June 14, 2021
COLLEGE STATION, TX / ACCESSWIRE / June 14, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has concluded definitive plans to advance its previously tested ITV-1 anti-HIV therapeutic...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Enzolytics Announces A Comprehensive Therapeutic Protocol For Production Of Monoclonal Antibodies To Address Ongoing And Future Pandemics
June 07, 2021
COLLEGE STATION, TX / ACCESSWIRE / June 7, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced a coherent protocol that it intends to execute to meet the Company's objective...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Regulatory Compliance
Enzolytics Announces the Discovery of Conserved, Immutable Target Sites on HTLV-1 and Plans To Commence Production of Monoclonal Antibodies Targeting These Sites
May 26, 2021
COLLEGE STATION, TX / ACCESSWIRE / May 26, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") today announced it has identified conserved, expectedly immutable sites on the HTLV-1 virus against...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use of Artificial Intelligence for Social Good
May 17, 2021
COLLEGE STATION, TX / ACCESSWIRE / May 17, 2021 /In a significant white paper, Enzolytics inc. (OTC PINK:ENZC) (http://enzolytics.com/) and Intel Corporation (https://www.intel.com) has published a...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Fraud
Regulatory Compliance
Enzolytics, Inc. Announces the Grant of a Distributorship License for the Right to Distribute its Anti-Hiv-1 Therapeeutic Itv-1 and a Stock Agreement Valued in Total At $7 Million US Dollars
May 12, 2021
COLLEGE STATION, TX / ACCESSWIRE / May 12, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has granted a distributorship license to a European pharma entity (the...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Enzolytics, Inc. Announces the Engaement of Ten Associates LLC As The Company's Strategic Communication Firm
May 11, 2021
COLLEGE STATION, TX / ACCESSWIRE / May 11, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has engaged TEN Associates LLC (the "Consultant") to assist the Company in...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Enzolytics Reports Progress On Its Multiple Therapeutics Platforms and Initiatives
April 19, 2021
COLLEGE STATION, TX / ACCESSWIRE / April 19, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company"). We continue to make great strides in the application of our multiple platforms for production...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Regulatory Compliance
Enzolytics to Present At the Emerging Growth Conference on April 14, 2021
April 12, 2021
Enzolytics Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. COLLEGE STATION, TX...
From
Enzolytics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.